Inclusion Criteria:

- Patients must have histologically or cytologically confirmed advanced malignant solid
tumor that has recurred or progressed following standard therapy, or that has not
responded to standard therapy, or for which there is no standard therapy, or who are
not candidates for standard therapy

- Patients must be > 18 years of age

- Patients of their legal representatives must be able to understand and sign an
informed consent form

- Patients must have evaluable or measurable tumor(s)

- Patients must be recovered from the effects of any prior surgery, radiotherapy or
other antineoplastic therapy. Up to CTCAE Grade 1 is acceptable for patients with
known peripheral neuropathy

- Women of childbearing potential as well as fertile men and their partners must agree
to abstain from sexual intercourse or to use an effective form of contraception
during the study and for 90 days following the last dose of MM-151 (an effective form
of contraception is an oral contraceptive or a double barrier method)

Exclusion Criteria:

- Patients for whom potentially curative antineoplastic therapy is available

- Patients who are pregnant or lactating

- Patients with an active infection or with an unexplained fever > 38.5°C during
screening visits or on the first scheduled day of dosing. (At the discretion of the
investigator, patients with tumor fever may be enrolled.)

- Patients with untreated and/or symptomatic CNS malignancies (primary or metastatic);
patients with CNS metastases who have undergone surgery or radiotherapy, whose
disease is stable, and who have been on a stable dose of corticosteroids for at least
2 weeks prior to the first scheduled day of dosing will be eligible for the trial